Clinical Trial

A Study of Vedolizumab in Children and Teenagers With Ulcerative Colitis or Crohn's Disease

Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
The main aim of this study is to learn how the body of a child or teenager with moderately to severely active ulcerative colitis (UC) or Crohn's disease (CD) processes vedolizumab (pharmacokinetics) given just under the skin subcutaneously (SC). The participants will be treated with vedolizumab for up to 34 weeks. During the study, participants will visit their study clinic several times.
Protocol Amendment History 1 change
notable Trial sites reduced: 57 -> 54 locations 2026-05-16
Trial Details
NCT Number NCT06100289
Lead Sponsor Takeda
Conditions Ulcerative Colitis, Crohn's Disease
Enrollment 70 participants
Start Date 2025-01-22
Primary Completion 2027-11-15 (estimated)
Study Completion 2027-11-15 (estimated)
Updated on ClinicalTrials.gov 2026-05-15